Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.34Last Year’s EPS
-4.4Same Quarter Last Year
Moderate Sell
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: 6.20%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects significant progress in cost reduction, revenue growth in key segments, and strategic expansion into new business areas, offset by ongoing net losses and challenges in the macroeconomic environment. The sentiment is cautiously optimistic with substantial achievements but also notable challenges.Company Guidance
During the earnings call, Ginkgo Bioworks provided significant guidance on their financial and strategic trajectory. The company reported a $205 million reduction in their annual run rate between Q1 2024 and Q1 2025, surpassing their target of $200 million by Q3 2025, and is on track to reach adjusted EBITDA breakeven by the end of 2026. They also highlighted their strong financial position with $517 million in cash and cash equivalents and no bank debt. Revenue from the Cell Engineering business grew by 37% year-over-year to $38 million, with a 32% increase in revenue-generating programs. Biosecurity revenue was reported at $10 million for the quarter with a segment gross margin of 28%. The call also included updated full-year revenue guidance, now expected to be between $167 million and $187 million, reflecting a $7.5 million noncash deferred revenue release. Additionally, the company emphasized their strategic progress in launching new tools businesses, such as Datapoints and Automation, as well as expanding opportunities with government clients, notably securing a $29 million ARPA-H contract.Significant Cost Reduction Achieved
Ginkgo Bioworks achieved a $205 million reduction in annual run rate costs between Q1 2024 and Q1 2025, exceeding the target of $200 million set for mid-2025.
Increase in Cell Engineering Revenue
Cell Engineering revenue increased by 37% to $38 million in Q1 2025 compared to Q1 2024. Excluding noncash revenue, the increase was 10%.
Strategic Expansion into Tools Business
Ginkgo Bioworks expanded its offerings to include tools business, Datapoints and Automation, aiming to diversify revenue streams and serve a broader customer base.
Improved Profitability and Cash Burn
Adjusted EBITDA improved from negative $117 million in Q1 2024 to negative $47 million in Q1 2025. Cash burn decreased from $104 million to $58 million year-over-year.
New Government Contracts
Ginkgo secured a $29 million ARPA-H contract and continues to work on 28 government projects with a significant backlog.
DNA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DNA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $6.45 | $7.40 | +14.73% |
Feb 25, 2025 | $10.29 | $9.11 | -11.47% |
Nov 12, 2024 | $8.39 | $8.60 | +2.50% |
Aug 08, 2024 | $11.43 | $10.81 | -5.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ginkgo Bioworks Holdings (DNA) report earnings?
Ginkgo Bioworks Holdings (DNA) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is Ginkgo Bioworks Holdings (DNA) earnings time?
Ginkgo Bioworks Holdings (DNA) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DNA EPS forecast?
DNA EPS forecast for the fiscal quarter 2025 (Q2) is -1.34.
